

Bentamapimod

SYN-1147

(Z)-2-(2-(4-(morpholinomethyl)benzyloxy)pyr imidin-4-yl)-2-(benzo[d]thiazol-2(3H)-ylidene)acetonitrile

CAS Registry No.: 848344-36-5

Smiles String:

c1ccc2c(c1)N/C(=C(/C#N)\c3ccnc(n3)OCc 4ccc(cc4)CN5CCOCC5)/S2

Molecular Weight: 457.55

Molecular Formula: C25H23N5O2S

Lot Number: Refer to vial

1H-NMR: Available on request


HPLC (Purity): > 95.0% @ 254 nm

ES-MS: Available on request


Description:

Bentamapimod (AS602801) is a novel and orally active c-Jun-N-Terminal Kinase Inhibitor highly specific for JNK kinases. The inhibitor Bentamapimod (AS602801) is a potent anti-inflammatory agent which has been shown to reduce the disease burden in several pre-clinical models for endometriosis, and has the potential to be effective in addressing the causes of post-operative abdominal adhesions. Pre-clinical data have demonstrated Bentamapimod to be an effective anti-inflammatory with anti-fibrotic properties. Bentamapimod (AS602801) showed good bioavailability in rats (F=50%) and Bentamapimod (AS602801) does cross the blood brain barrier, with 98% brain penetration and so far the drug has been well tolerated. Bentamapimod (AS602801) is a potent and selective JNK inhibitor with therapeutic potential in MS and fibrosis as well.

Biological Activity



Kinome Mapping



Shipping and Storage Temperature

Shipping:

Ambient

Storage:

2 years -20C, Powder 1 month, -4C in DMSO, More than one month -80C in DMSO

Solubility

10.8 mg/mL in DMSO

Preparing Stock Solutions

Stock Solution (1ml DMSO)	1mM	10mM	20mM	50mM
Mass(mg)	0.4576	4.5760	9.1520	22.8800

References

1. Adcock IM, Caramori G. Kinase targets and inhibitors for the treatment of airway inflammatory diseases: the next generation of drugs for severe asthma and COPD? BioDrugs. 2004;18(3):167-80.

Ordering Information

To order more of this or any other SYNkinase compound, go to synkinase.com, Call us Toll Free (US Only) at 1-877-854-6273 or email orders@synkinase.com.

Product Datasheet (Rev. 1.1)